Results 91 to 100 of about 65,210 (242)
Orally administered, pH‐responsive Co‐SAN exerts dual functions: in the alkaline intestinal milieu, it scavenges reactive oxygen species (ROS) and suppresses the PI3K/AKT pathway and NETs formation, thus providing radioprotection; whereas in the acidic tumor microenvironment, it generates ROS and alleviates hypoxia, thereby enhancing radiosensitization.
Shengqi Yin +13 more
wiley +1 more source
IMM‐H018, a dual IDO1/NE inhibitor, demonstrates potent therapeutic efficacy in sepsis by simultaneously targeting excessive inflammation and immune dysfunction. It prevents both primary and secondary sepsis through anti‐inflammatory, immune‐restoring, and renoprotective mechanisms, reducing organ damage, improving immune homeostasis, preserving kidney
Yi Zhou +11 more
wiley +1 more source
Hospital‐treated infections are linked to increased risk of inflammatory bowel disease in a large prospective cohort. This risk differs by infection burden, time since infection, and host immune‐genetic susceptibility. The findings support a multi‐hit pathogenesis model in which severe infection and inherited susceptibility jointly shape inflammatory ...
Haiming Zhuang +16 more
wiley +1 more source
Engineering of the 148‐germline (148‐GL) antibody reveals a roadmap for overcoming SARS‐CoV‐2 viral escape. By introducing four specific somatic hypermutations, the resulting 148‐M4 variant restores potent neutralization against Omicron BA.1 and BA.4/5.
Huibin Lv +14 more
wiley +1 more source
This study examines the relationship between hospital financial performance and operational efficiency. Using data from the American Hospital Association (AHA), we find that profitability, debt coverage, and working capital efficiency are positively ...
Chulho Christopher Lee +5 more
doaj +1 more source
Preparing for the Aftermath of COVID-19: Important Considerations for Health Care Providers and Hospital Administrators. [PDF]
Holthof N.
europepmc +1 more source
Cell‐Selective Delivery of RIBOTACs via an Anti‐EGFR Nanobody for Pancreatic Cancer Treatment
This study introduces an innovative strategy for the tumor‐selective catalytic degradation of oncogenic non‐coding RNA by interfacing a ribonuclease‐recruiting small molecule (RIBOTAC) with an EGFR‐targeting nanobody via a CTSB (Cathepsin B)‐responsive linker.
Tianli Luo +15 more
wiley +1 more source
A programmable encapsulation technology is developed to reduce bacterial immunogenicity and proliferation after systemic administration. The cross‐linked polymer networks around individual bacteria enable immunogenic shielding and permit selective proliferation in tumors, allowing the bacteria to convert tumor‐accumulated ammonia into L‐arginine and ...
Jianhui Yang +12 more
wiley +1 more source

